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Abstract
Behavioral sensitization to psychostimulants manifests as an increased locomotor response with
repeated administration. Dopamine systems are accepted to play a fundamental role in sensitization,
but the role of specific dopamine receptor subtypes has not been completely defined. This study used
the combination of dopamine D2 receptor-deficient mice and a D1-like antagonist to examine
dopamine D1 and D2 receptor involvement in acute and sensitized locomotor responses to
methamphetamine. Absence of the dopamine D2 receptor resulted in attenuation of the acute
stimulant effects of methamphetamine. Mutant and wild-type mice exhibited sensitization that lasted
longer within the time period of the challenge test in the mutant animals. Pretreatment with the D1-
like receptor antagonist SCH 23390 produced more potent reductions in the acute and sensitized
locomotor responses to methamphetamine in D2 receptor-deficient mice than in wild-type mice;
however, the expression of locomotor sensitization when challenged with methamphetamine alone
was equivalently attenuated by previous treatment with SCH 23390. These data suggest that
dopamine D2 receptors play a key role in the acute stimulant and sensitizing effects of
methamphetamine and act in concert with D1-like receptors to influence the acquisition of
methamphetamine-induced behavioral sensitization, traits that may influence continued
methamphetamine use.
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The physical and psychological effects of methamphetamine are due, in part, to elevation of
synaptic monoamine levels, resulting from the disruption of plasma membrane monoamine
transporter function and induction of extravesicular release of stored monoamines
(Fleckenstein et al. 2000; Kilty et al. 1991). Sensitivity to methamphetamine likely influences
susceptibility to escalating drug use. In fact, the initial stimulant response to amphetamine has
been found to predict the likelihood of further drug use (Gabbay 2003; de Wit et al. 1986).
Although multiple neurochemical factors are known to influence responses to psychomotor
stimulants (see recent review by Phillips et al. 2008), the complete abrogation of the behavioral
activating effects of cocaine in dopamine D1 receptor-deficient mice (Xu et al. 1994a, 2000),
and the exaggerated excitatory effect of cocaine and methamphetamine in dopamine D4
receptor-deficient mice (Rubinstein et al. 1997), show the importance of dopamine receptors
(Neve et al. 2004) in mediating these responses.
Repeated amphetamine exposure induces neural changes that are detectable through behavioral
and biochemical analyses. This ‘sensitization’ has been most often studied in rodents (Down
& Eddy 1932; Pierce & Kalivas 1997), but also documented in humans (Boileau et al. 2006;
Sax & Strakowski 2001) and may contribute to transitions in drug use from the controlled to
compulsive patterns characteristic of addiction (Kalivas et al. 2005; Robinson & Berridge
1993; Ron & Jurd 2005). Disruption of sensitization to amphetamine with pharmacological
antagonists shows the importance of dopamine receptors in this process and suggests the
involvement of both families of receptor subtypes. D1-like receptor antagonists given
systemically block both the acquisition and expression of locomotor sensitization to
amphetamine (Hamamura et al. 1991; Karper et al. 2002; Kuczenski and Segal 1999; Ujike
et al. 1989; Vezina, 1996; Vezina and Stewart, 1989), whereas D2-like receptor antagonists
have been found to block the expression (Kuczenski and Segal 1999) and the acquisition in
some (Hamamura et al. 1991; Ujike et al. 1989), but not other (Vezina 1996; Vezina and
Stewart 1989) studies.
A complementary approach involves the use of gene deletion to examine the involvement of
specific receptor subtypes. Variable methods and differences in genetic background may
explain the apparent inconsistencies in results in D1 receptor-deficient mice for studies of the
acute and sensitized responses to amphetamine (Crawford et al. 1997; Karper et al. 2002;
McDougall et al. 2005; Xu et al. 2000), and no papers have reported locomotor effects of
amphetamine in D2 receptor (D2R)-deficient mice. Glickstein and Schmauss (2004) reported
a reduced magnitude of repeated methamphetamine-induced stereotypy in D2R-deficient mice.
Therefore, reduced susceptibility to locomotor sensitization in the D2R-deficient mice might
be predicted, although reduced susceptibility to stereotypy could lead to increased ability to
exhibit locomotor sensitization. In addition, we studied the combination of D2R-deficiency
and pharmacological antagonism to explore the role of dopamine D1-like receptors in the
complete absence of D2 receptors. We predicted that the D1-like receptor antagonist would
attenuate sensitization, but would perhaps have a more profound effect in D2R-deficient mice
because of possible compensatory changes resulting in increased dependence upon D1-like
receptors in the absence of D2. This approach complements the alternative approach of co-
administration of two antagonist drugs and is powerful for identifying specific roles for each
of the receptor subtypes.
Materials and methods
Animals
The generation and basic phenotypic analysis of the B6. 129S2-Drd2tm/low strain of D2R-
deficient mice used in this study have been described previously (Kelly et al. 1997; 1998).
Mice used here were the offspring of incipient congenic mice that had been backcrossed for
five generations to the C57BL/6J (B6) strain. Ten- to 12-week-old litter-mates of both sexes,
Kelly et al. Page 2
Genes Brain Behav. Author manuscript; available in PMC 2009 September 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
born to heterozygous breeder pairs, were used. Mice were group-housed (2–5 per cage) except
during testing. Genotypes were determined by Southern blot analysis as described previously
(Kelly et al. 1997). Studies were approved by the Institutional Animal Care and Use
Committees of Oregon Health & Science University and the VA Medical Center and were
carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted
and promulgated by the National Institutes of Health.
A total of 196 mice were studied (95 wild type and 101 D2R deficient), divided equally by
sex. The large number of animals, experimental design and available equipment necessitated
the consecutive testing of three cohorts of mice (69, 88 and 39 in cohorts 1, 2 and 3,
respectively). Genotype, sex and treatment group were equated within each cohort. Results
from the first cohort of mice led us to include two higher dose SCH 23390 groups (SCH 0.1
mg/kg and saline, SCH 0.1 mg/kg and methamphetamine) in cohorts 2 and 3.
Locomotor activity testing
Test duration on all days was 60 min, and data were collected in 5-min periods. There were 10
treatment groups per genotype, for a total of 20 groups (n = 9–11/subgroup). The activity
apparatus (AccuScan Instruments, Inc., Columbus, OH, USA) and paradigm for sensitization
have been described previously (Phillips et al. 1994), and the published procedures were
followed with only slight modifications. On all test days, mice received two i.p. injections
spaced 30-min apart. The injection time interval was chosen to allow a 30-min absorption
period on days when the D1-like receptor antagonist SCH 23390 (Sigma/RBI, St Louis, MO,
USA; 0.003, 0.01, 0.03 or 0.1 mg/kg prepared in 0.9% saline) was administered; the second
injection was administered immediately before testing. Because SCH 23390 is an antagonist
of both D1 and D5 dopamine receptors, we have characterized it as a D1-like receptor
antagonist throughout this paper. To allow acclimation to the locomotor activity monitors and
test procedures, and to obtain baseline activity data, two consecutive days of testing were
conducted with saline injections. There were then 4 days spaced 48 h apart (days 3, 5, 7 and 9
of the experiment) on which saline or SCH 23390 was administered prior to saline or 2 mg/kg
(+)-methamphetamine (Sigma, St Louis, MO, USA; prepared in 0.9% saline) to study the
effects of SCH 23390 on basal activity and on the acquisition and expression of
methamphetamine-induced sensitization. Two days after the last SCH 23390 treatment (day
11), all mice were tested after a challenge treatment with 2 mg/kg methamphetamine, that was
preceded by a saline injection (no animals received SCH 23390 on the methamphetamine
challenge day). The expression of a larger locomotor response to methamphetamine in
methamphetamine pre-exposed mice on this test day would indicate that sensitization to
methamphetamine had been acquired, and this test allowed us to determine whether prior SCH
23390 treatment affected this expression. On the final test day (day 12), mice were treated with
two saline injections to assess the possibility of contextual sensitization. All mice were
euthanized following locomotor testing on this day. SCH 23390 doses were chosen from
previous studies and from initial responses in the current study that were effective in attenuating
drug stimulant effects (Kuribara 1995; Kuribara & Uchihashi 1994; Shen et al. 1995). The
dose of methamphetamine was chosen to induce acute stimulation and sensitization (Kamens
et al. 2005; Phillips et al. 1994), but was well below doses known to induce stereotypic
behaviors in mice (Atkins et al. 2001; Glickstein & Schmauss 2004; Karler et al. 1998; Yates
et al. 2007).
Statistics
Data were analyzed initially by multifactor analysis of variance (ANOVA) (with repeated measures
when appropriate) using the raw values for total horizontal distance traveled in 60 min
(Statview 5.0.1; SAS Institute, Inc., Cary, NC, USA or Stastica; StatSoft, Inc., Tulsa, OK,
USA). Complex interactions were further investigated with successive ANOVAs including fewer
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factors. The sources of two-way interactions were determined using simple main effect
analyses. The Tukey highly significant difference (HSD) test was used for mean comparisons.
To examine the effects of SCH 23390 alone and in combination with methamphetamine,
sigmoidal dose–response curves were fitted for each of the four drug days during the acquisition
of sensitization period, using non-linear regression analysis. Half-maximal inhibitory dose
(ID50) values ± 95% confidence intervals were then calculated for either SCH 23390 and saline
or SCH 23390 and methamphetamine on each day with PRISM 3.0cx (GraphPad Software, Inc.,
San Diego, CA, USA). To combine data sets across all 4 days, the individual values were
normalized relative to the respective groups’ mean values for 60-min horizontal distance from
saline day 2.
Results
Acute locomotor responses to methamphetamine are diminished in D2R-deficient mice
Only data from mice treated with saline and methamphetamine in the absence of SCH 23390
treatment are represented in Fig. 1. These data were analyzed separately from those for the
SCH 23390 treatment groups to determine locomotor responses to acute and repeated
methamphetamine. Repeated measures ANOVA identified a significant three-way interaction of
genotype, drug and day (F7,252 = 4.5, P < 0.001). The findings in animals treated with saline
were similar to our previously reported results (Kelly et al. 1998), wherein D2R-deficient mice
exhibited reduced locomotor activity (horizontal distance traveled) in comparison to their wild-
type siblings. This conclusion was substantiated by a significant interaction of genotype and
day within the repeated saline-treated groups (F7,126 = 5.5, P < 0.001), and simple main effect
analyses that detected differences between the wild-type and D2R-null mice of this treatment
group on all saline test days (open symbols in Fig. 1a).
The stimulant response of D2R-deficient mice upon initial exposure to methamphetamine was
less robust and shorter lasting than that of wild-type controls (Fig. 1b). This conclusion was
substantiated by the following statistical outcomes. First, there was a significant genotype by
drug group interaction for total horizontal distance traveled, when data for drug day 1 (Fig. 1a)
were compared for saline vs. methamphetamine groups (F1,36 = 8.3, P < 0.01). Both genotypes
exhibited stimulation in response to methamphetamine, but the difference between genotypes
was larger after methamphetamine treatment than after saline treatment. A second, time–course
analysis more completely characterizes the acute methamphetamine response (Fig. 1b).
Repeated measures ANOVA identified a significant genotype × drug × time (5-min segments)
interaction (F11,396 = 7.1, P < 0.001) that was associated with an attenuated amplitude and
duration of methamphetamine-induced locomotor stimulation in D2R-deficient compared with
wild-type mice. Within each genotype, simple main effect analyses identified significant
effects of time for the methamphetamine-treated mice (both P < 0.01). Locomotor values
during the first 10 min of the test were similar for mutant and wild-type mice and showed a
similar level of elevation above their respective saline-treated groups. However, in wild-type
mice, locomotion continued to increase and remained significantly elevated above their initial
5-min response across minutes 10–50 (Tukey HSD test; all P < 0.05), whereas locomotion was
elevated above the initial 5-min response for only minutes 10–20 in the D2R-null mice (P <
0.05).
D2 receptor-deficient mice express similar levels of sensitization across days, but
sensitization to methamphetamine within the time period of the challenge test lasts longer
Both D2R-deficient mice and wild-type mice showed progressive locomotor sensitization to
repeated methamphetamine across treatment days (Fig. 1a). There was no significant difference
between genotypes in their magnitude of sensitization when data were accumulated across the
entire 60-min test session, either when assessed by analysis of covariance with response on the
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first drug day serving as the measure of acute drug response (F1,17 = 0.05, P = 0.82 for the
effect of genotype) or by a two-factor ANOVA (F1,36 = 0.08, P = 0.77 for the genotype by drug
group interaction). However, to better characterize expression of the sensitized response, the
locomotor time–course on the methamphetamine challenge day was examined (Fig. 1c). There
was a three-way interaction of genotype, drug and time (F11,396 = 2.2, P < 0.05). Independent
ANOVAs showed significant drug (saline vs. methamphetamine) × time interactions for both D2R-
null (F11,198 = 3.3, P < 0.001) and wild-type mice (F11,198 = 8.2, P < 0.001). Again, as seen
in Fig. 1b, activation was sustained for longer in the wild-type mice compared with the D2R-
null mice, regardless of whether they were receiving methamphetamine for the first or fifth
time. However, when the acute and repeated treatment groups were compared within genotype,
sensitization within the 60-min challenge test lasted longer in the D2R-null mice, with
significant differences between the acute and repeated methamphetamine treatment groups at
all 5-min time periods throughout the 60-min session in these mice and for only the first three
5-min periods for the wild-type mice.
Analysis of time–course data for mice challenged with saline on the contextual test day (not
shown), showed no significant interaction of genotype, prior drug treatment and time
(F11,396 = 0.95, P = 0.49); however, there was a genotype × treatment interaction for the total
locomotion exhibited during the 60-min time period (F1,36 = 4.9, P < 0.05). Simple main effects
analyses indicated some contextual conditioning in the D2R-null mice (scores were greater in
mice that had received repeated treatments with methamphetamine in this context than in mice
that had received mostly saline), but not in the wild-type mice.
D2 receptor-deficient and wild-type mice have comparable responses to D1-like receptor
antagonism in the absence of methamphetamine treatment
Figure 2a summarizes the locomotor response data for D2R-deficient and wild-type mice after
acute and repeated treatment with SCH 23390 in the absence of methamphetamine on the first
(day 1) and final (day 4) drug days during the acquisition phase. Data for days 2 and 3 were
intermediate to those for days 1 and 4 and are not shown in Fig. 2a for clarity. A repeated
measures ANOVA (SCH 23390 dose × genotype × day) for the 60-min time period on all four drug-
treatment days showed significant main effects of genotype (F1,87 = 92.0, P < 0.0001), SCH
23390 dose (F4,87 = 14.8, P < 0.0001) and day (F3,261 = 24.1, P < 0.0001). There was also a
significant interaction of genotype and day (F3,261 = 9.9, P < 0.0001) and of genotype and SCH
dose (F4,87 = 3.7, P < 0.01). The source of the genotype × day interaction was greater locomotor
activity in wild-type compared with D2R-null mice on the final SCH 23390 test day (day 4,
Fig. 2a). The source of the genotype × SCH dose interaction was the relatively low activity
levels only in the D2R-null group treated with saline (0 mg/kg SCH dose).
Because of the significant baseline differences in locomotor activity between wild-type and
D2R-null mice, we normalized the SCH 23390 dose–response data to 100% of activity on
saline day 2 for each treatment group, collapsed across all four drug-treatment days. This
permitted comparison of the shapes of the dose–response curves (Fig. 2b). The Hill slopes of
the sigmoidal dose–response curves were held constant at −1.5. The calculated ID50 values
and 95% confidence intervals for SCH 23390 from these functions were 0.053 mg/kg (0.032–
0.090) for wild-type mice and 0.040 mg/kg (0.024–0.068) for D2R-null mice, which were not
significantly different from each other (t93 = 0.77, P = 0.44, two-tailed t-test). Similar ID50
values were obtained for each genotype from the daily regression curves based on the raw
activity data in Fig. 2a, validating our secondary analysis of the data normalized to percentage
of saline day 2. Overall, these results show that despite the baseline hypoactivity in D2R-null
mice, both genotypes responded with similar sensitivity to acute blockade of the D1-like
receptor by SCH 23390 in the absence of methamphetamine.
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D2 receptor-deficient mice are more dependent on D1-like receptor activation for their
excitomotor responses to methamphetamine compared to wild-type controls
Figure 3a summarizes the locomotor responses of D2R-deficient and wild-type mice after acute
and repeated treatment with SCH 23390 in the presence of methamphetamine on the first (day
1) and final (day 4) drug days during the acquisition period. A repeated measures ANOVA of
activity across all four drug-treatment days showed significant main effects of genotype
(F1,89 = 88.2, P < 0.0001), dose of SCH 23390 (F4,89 = 29.5, P < 0.0001) and day (F3,267 =
44.8, P < 0.0001). There were also significant interactions of genotype and SCH 23390 dose
(F4,89 = 3.1, P < 0.02), genotype and day (F3,267 = 2.7, P < 0.05), and SCH 23390 dose and
day (F12,267 = 1.8, P < 0.05), but no significant three-way interaction (F12,267 = 1.2, P = 0.28).
The absolute levels of activity were lower in D2R-null vs. wild-type mice, consistent with their
difference in basal activity level. However, both genotypes exhibited significant induction of
sensitization from day 1 to day 4 (follow-up ANOVAS on the individual genotypes: F3,129 = 22.8,
P < 0.0001 for wild-type mice; F3,138 = 24.1 and P < 0.0001 for D2R-null mice).
Data were normalized relative to 100% of activity for each respective treatment group on saline
day 2 and collapsed across all four drug days to directly compare the shapes of the dose–
response curves (Fig. 3b). In contrast to the similar potency of SCH 23390 to decrease basal
locomotor activity between genotypes (shown in Fig. 2b), the dose–response curve for SCH
23390 plus methamphetamine was shifted significantly to the left in the D2R-deficient mice,
relative to the wild-type mice. ID50 values and 95% confidence intervals for SCH 23390
indicated that its potency was increased approximately threefold in the D2R-null mice [0.010
mg/kg (0.006–0.016)] compared with wild-type mice [0.031 mg/kg (0.019–0.049)] (t95 = 3.5;
P < 0.001, two-tailed t-test). In other words, SCH 23390 attenuated methamphetamine-induced
activation to a greater extent at lower doses in D2R-deficient than in wild-type mice. The same
relative shift in dose–response curves between genotypes was observed for all four individual
drug days using either the raw locomotor data for horizontal distance traveled or data
normalized as a percentage of saline day 2 (not shown).
The curves shown in Fig. 3a were used to calculate the dose of SCH 23390 that reduced
locomotor activity on day 4 to the equivalent of the Bmax acute response to methamphetamine
on day 1 for each genotype. This analysis yielded values of approximately 0.008 mg/kg for
D2R-deficient mice and 0.03 mg/kg for wild-type mice. The approximately threefold greater
dose in wild-type mice closely mirrors the difference in SCH 23390 potency from the calculated
ID50 values to reduce the excitomotor response to methamphetamine when data were collapsed
across the four drug days (Fig. 3b).
D1-like receptor antagonist pretreatment blocks the subsequent expression of
methamphetamine sensitization in both D2R-deficient and wild-type mice
Locomotor activity on the methamphetamine challenge day was compared among all treatment
groups, with genotype included as a factor. ANOVA showed significant main effects of genotype
(F1,175 = 122.9, P < 0.0001) and treatment group (F9,175 = 5.2, P < 0.0001) but no significant
interaction between the two factors. Fig. 4a and 4b summarize the data separated by genotype
and for clarity, only the highest dose SCH 23390 groups (SCH 23390 0.1 mg/kg alone or SCH
23390 0.1 mg/kg and methamphetamine). Pretreatment with this dose of the D1-like receptor
antagonist during repeated methamphetamine administration blocked the expression of
methamphetamine sensitization in both wild-type mice and D2R-deficient mice (Tukey HSD;
P < 0.05, Sal/Meth compared to SCH 0.1/Meth). This effect was specific for sensitization
because repeated administration of high dose SCH 23390 without methamphetamine did not
prevent a robust acute locomotor response to methamphetamine on the challenge day (Sal/Sal
compared to SCH 0.1/Sal; also compare activity levels in Fig. 4 panels a and b with those in
panels c and d).
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Locomotor activity data from all treatment groups on the contextual day when all animals
received only saline injections were also compared, with data grouped on genotype. A two-
factor ANOVA showed significant main effects of genotype (F1,175 = 159.7, P < 0.0001) and
treatment group (F9,175 = 2.3, P < 0.02) with no significant interaction. Examination of the
data presented in Fig. 4c and d suggests that drug-treatment history and context-dependent
effects were minimal (no significant mean differences among the four groups shown were
detected by pairwise Tukey HSD post hoc comparisons).
Discussion
Sensitivity to some effects of amphetamine has a heritable component (Crabbe et al. 1983;
Kamens et al. 2005; Palmer et al. 2005; Phillips et al. 2008) that could influence addiction
risk. Specific genes have not yet been identified that lead to an increased probability of
methamphetamine abuse; however, single gene mutant methods have been increasingly used
to study relevant mechanisms. The combination of a dopamine D2 receptor deficiency with a
D1-like receptor pharmacological antagonist was used to examine the roles of dopamine D1-
like and D2 receptors in acute and sensitized methamphetamine responses. The first novel
finding was a significant reduction in the amplitude and duration of the methamphetamine
response in D2R-deficient mice, whether they were receiving methamphetamine for the first
time or after several prior exposures. However, although the magnitude of sensitization was
unaffected by the absence of the D2R when examined across daily sessions, the duration of
sensitization within the time period of the final methamphetamine challenge was increased in
D2R-deficient compared with wild-type mice, when the response of mice treated for the first
time was compared to the response of those receiving their fifth treatment with
methamphetamine. The hypothesis that D1-like receptors play an important role in the acute
methamphetamine response, as well as the acquisition and expression of sensitization, was
supported by data showing that SCH 23390 attenuated each of these responses. However, an
increased role of D1-like receptors was shown by examining the effect of the antagonist in the
D2R null mutant mice; D2R-deficient mice were more sensitive to the effects of the D1-like
receptor antagonist on both the acute and sensitized methamphetamine responses. Changes in
D1 receptors and D1-receptor modulated pathways might be predicted to occur in this
constitutive knockout. However, the two genotypes were equally sensitive to the effects of
SCH 23390 on basal locomotor activity, suggesting that the increased role of D1-like receptors
in methamphetamine response in the D2R-deficient mice is not due solely to D1 receptor-
related compensatory changes. Taken together, our results support the hypothesis that the
dopamine D2 receptor acts in concert with D1-like receptors, in the mechanisms underlying
methamphetamine stimulation and sensitization.
Both D1-like and D2 dopamine receptors are necessary for maximum acute
methamphetamine response
The importance of dopamine D2 receptors in locomotor activity is well established, and these
studies confirm and expand upon previous work that found a de novo locomotor phenotype in
D2R-deficient mice (Baik et al. 1995; Kelly et al. 1998). When data were corrected for baseline
activity differences, a decrease in the amplitude and duration of the acute locomotor stimulant
effects of methamphetamine was apparent in D2R-deficient mice (Fig. 1b). When pretreated
with SCH 23390 before methamphetamine treatment, a greater dependency of the D2R-
deficient mice on D1-like receptors for their methamphetamine stimulant response was seen
(Fig. 3). This result might not have been predicted from a study that showed that c-fos
expression in response to methamphetamine was equivalently reduced by pretreatment with
SCH 23390 in D2R-deficient and wild-type mice (Schmauss 2000). However, behavior was
not measured in that study and this marker of neural activity was examined in the neocortex
and not the limbic regions thought to influence locomotor behavior. The importance of D1-
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like and D2 receptor co-activation in producing a maximal response is not unique to our study
(Glickstein and Schmauss 2004; Xu et al. 1997).
The increased reliance on D1-like receptors for methamphetamine sensitivity in the mutant
mice was not the case for spontaneous locomotor activity; SCH 23390 suppressed locomotor
activity equally regardless of D2 receptor status (Fig. 2b). Because D1 receptor-deficient mice
were reported to be impervious to the hypokinetic and cataleptic effects of high doses of SCH
23390 (Xu et al. 1994b), it is unlikely that SCH 23390 was acting on other dopamine receptors.
This suggests that the compensatory adaptation allowing relatively normal (although somewhat
impaired; see Kelly et al. 1998) basal locomotor activity in D2R-deficient mice is not mediated
solely by signaling through the dopamine D1 receptor.
Methamphetamine sensitization is of similar magnitude, but has a longer time–course in
D2R-deficient mice
Despite the reduction in the acute stimulatory effects of methamphetamine in D2R-deficient
mice, locomotor sensitization developed over the course of repeated methamphetamine
administration in these animals. No significant difference from wild-type siblings was found
in the magnitude of sensitization during the acquisition period. However, on the
methamphetamine challenge day, behavioral sensitization lasted longer in the D2R-deficient
compared with wild-type mice. This longer time–course of sensitization (longer-lasting
elevation of activity after methamphetamine treatment in the methamphetamine pre-exposed
vs. non-pre-exposed mice) in the D2R-null mice was accompanied by a steeper decline in
stimulation after methamphetamine challenge. A difference between the null mutant and wild-
type mice in susceptibility to methamphetamine-induced stereotypy (Glickstein & Schmauss
2004), which might compete with the locomotor behavior, cannot be ruled out. However, doses
of amphetamine that induce acute and sensitized stereotypic responses have typically been
larger than the dose used here, and the administration often more frequent (Atkins et al.
2001; Battisti et al. 1999; 2000; Glickstein & Schmauss 2004; Karler et al. 1998; Yates et
al. 2007). One study simultaneously measured stereotypic and locomotor behaviors following
treatment with several doses of D-amphetamine in C57BL/6J mice, the background strain of
the mice used in our studies (Yates et al. 2007). During the 60-min test period corresponding
to our study, a 6 mg/kg dose of amphetamine induced robust stimulation that was interrupted
by stereotypy. However, stimulation with no stereotypy was seen after a 2 mg/kg dose. Blunted
neuronal activation in the striatum indexed by measuring c-fos expression in response to
acutely and repeatedly administered methamphetamine corresponded with resistance of the
D2R-deficient mice to methamphetamine-induced stereotypy (Glickstein and Schmauss
2004). We have previously found that mice extremely sensitive to the acute stimulant effects
of methamphetamine are less likely to self-administer methamphetamine (Kamens et al.
2005). The blunted stimulant response of the D2R-null mice in combination with reduced
sensitivity to stereotypy and elongated duration of sensitization might predict greater
susceptibility to methamphetamine self-administration and relapse. To our knowledge, D2R-
null mutant mice have not been tested for methamphetamine reward-related traits.
Overall, our results indicate that the D2 receptor is not essential for methamphetamine-induced
sensitization acquisition or expression, but may be important for duration. However, our
findings differ from previous pharmacological studies in mice that utilized YM-09151-2 (a
D2-like antagonist), or SCH 23390, to effectively block sensitization to methamphetamine
(Kuribara & Uchihashi 1993, 1994). There are several possible explanations for these disparate
findings. First, the pharmacological studies utilized a different mouse strain (the dd strain) that
was apparently much more sensitive to the locomotor depressant effects of SCH 23390 than
C57BL/6J mice, the background strain used here. Second, those studies administered drugs by
s.c. rather than i.p. injection, which may have produced differences in the pharmacokinetics
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of drug action. Third, the methamphetamine was administered at longer intervals in the
published work; there were 3–4 days between treatments compared to 48 h in our study.
However, previous studies have shown our sensitization paradigm to be effective in C57BL/
6J mice (Phillips et al. 1994). Fourth, D2-like antagonists may also affect D3 receptor signaling
pathways that have been postulated to play a role in behavioral sensitization (Jones et al.
2007; Chiang et al. 2003). Finally, another possible explanation for the different conclusions
from the purely pharmacological and genetic studies is that developmental compensations in
the relevant circuitry of D2R-deficient mice have changed other aspects of the response system.
Perhaps the difference in within-treatment duration reflects the increased dependence on D1-
like receptor signaling by the D2R-null mice. A conditional receptor gene inactivation strategy
is necessary to fully resolve this issue. In addition to bypassing critical developmental time
points when neural adaptations may readily occur, a conditional mutant could also be used to
discriminate spatially between ventral tegmental and ventral striatal substrates that are
postulated to underlie different aspects of behavioral sensitization (Cador et al. 1995; Pierce
& Kalivas 1997; Tanabe et al. 2004).
D1-like receptors are essential for the acquisition and expression of sensitization in wild-
type and D2 receptor-deficient mice
Cador et al. (1995) have argued that acquisition and expression of psychostimulant
sensitization are separable processes with distinct neural substrates. However, previous
pharmacological studies in wild-type mice have shown that SCH 23390 dose-dependently
attenuated both the acquisition and expression of methamphetamine sensitization (Kuribara &
Uchihashi 1993, 1994). Our results in wild-type mice are concordant with these findings. They
are also similar in that expression of sensitization on the methamphetamine challenge day was
only prevented by SCH 23390 pretreatment (in combination with methamphetamine) at doses
that nearly completely inhibited the locomotor stimulant response on the drug test days during
acquisition. The consequences of SCH 23390 pretreatment during acquisition for the
expression of methamphetamine sensitization on the methamphetamine challenge day were
qualitatively the same in D2R-deficient and wild-type mice.
The amplitude and duration of the initial locomotor response to methamphetamine, but not the
induction of behavioral sensitization, was significantly impaired by constitutive absence of the
dopamine D2 receptor. During the challenge test, sensitization was sustained for a longer period
of time in D2R-deficient mice. Our data are consistent with some other findings suggesting
that the D1 receptor serves a more critical function than the D2 receptor in the acquisition of
methamphetamine-induced behavioral sensitization. The literature is silent with regard to
studies utilizing D1 and D2 receptor antagonist co-administration to study psychostimulant
sensitization. However, the finding that D1-like receptors played a more significant role in the
sensitized response to methamphetamine in D2R-deficient animals than in their wild-type
siblings supports the involvement of D2 receptors as well. Taken together, these studies
indicate that both receptors are needed for maximal stimulant response to methamphetamine,
and at least one of the two major dopamine receptor subtypes must be functional for the
acquisition and expression of sensitization.
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Figure 1. Locomotor activity of D2R-deficient and wild-type mice in response to single or repeated
administration of methamphetamine
(a) Summary of the locomotor responses of D2R+/+ and D2R−/− mice to repeated administration
of saline or 2 mg/kg methamphetamine (Meth) followed by Meth and contextual-cue
challenges during the 2-week experiment. The total horizontal distance traveled during each
study day’s 1-h test session is graphed; mean ± SEM; n = 10 per group. Repeated saline group
mice received saline injections on all days except the Meth challenge day. Repeated Meth
group mice received Meth injections on the drug days and Meth challenge day. See Materials
and Methods for a more complete description of the experimental design and subgroups. (b)
D2R−/− mice had a reduced excitomotor response when compared to D2R+/+ mice after an
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initial injection of 2 mg/kg methamphetamine on drug day 1. The time–courses of the
locomotor responses to saline and methamphetamine are shown in 5-min periods over a total
of 1 h; mean ± SEM; n = 10 per group. (c) D2R−/− mice exhibited comparable, but more
sustained, locomotor sensitization compared to D2R+/+ mice on the Meth challenge day. The
time–courses of the locomotor responses to methamphetamine are shown in 5 min periods over
a total of 1 h; mean ± SEM; n = 10 per group.
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Figure 2. The D1R antagonist SCH 23390 inhibited basal locomotor activity in D2R-deficient and
wild-type mice
(a) Dose–response curves for horizontal distance traveled in 60 min from drug days 1 and 4 in
groups of mice injected with the indicated doses of SCH 23390 followed by saline; mean ±
SEM, n = 9 to 11 per group. The non-linear regression curves for the D2R−/− mice only excluded
the 0 mg/kg dose to allow convergence of the data. (b) Dose–response curves generated with
the combined data from drug days 1 to 4 after normalization of all points to 100% of the mean
locomotor activity on saline day 2 for the respective groups; mean ± SEM, n = 9 to 11 per
group.
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Figure 3. The D1R antagonist SCH 23390 inhibited methamphetamine-stimulated locomotor
activity in D2R-deficient and wild-type mice
(a) Dose–response curves for horizontal distance traveled in 60 min on drug days 1 and 4 in
groups of mice injected with the indicated doses of SCH23390 followed by 2 mg/kg
methamphetamine; mean ± SEM, n = 8 to 11 per group. (b) Dose–response curves generated
with the combined data from drug days 1 to 4 after normalization of all points to 100% of the
mean locomotor activity on saline day 2 for the respective groups; mean ± SEM, n = 8 to 11
per group. The curve was shifted significantly to the left in D2R-deficient mice.
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Figure 4. The D1R antagonist SCH 23390 blocked the expression of methamphetamine (Meth)
sensitization in D2R-deficient and wild-type mice
Total horizontal distance traveled in 60 min is shown for the Saline (Sal)/Sal Sal/Meth, SCH
0.1/Sal, and SCH 0.1/Meth treatment groups on the Meth challenge day (a, wild-type mice;
and b, D2R-deficient mice) and the contextual challenge day (c, wild-type mice; and d, D2R-
deficient mice); mean ± SEM, n = 10 per group. Pretreatment of mice with SCH in combination
with Meth on the four drug-treatment days blocked the expression of methamphetamine
sensitization in both genotypes. However, pretreatment with SCH only did not block the acute
locomotor excitatory effect of methamphetamine on the Meth challenge day or cause lower
basal locomotor activity on the contextual challenge day in either genotype.
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